M. Schreeder

J. Hainsworth, H. Burris, D. Yardley, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Ublituximab and Umbralisib in Relapsed/ Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.

J. Vose, C. Flowers, S. O'brien, 2019, Blood.

An Integrated Safety Analysis of the Next Generation PI3Kδ Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies

J. Burke, J. Vose, J. Gribben, 2017 .

Ublituximab (TG‐1101), a novel glycoengineered anti‐CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial

J. Burke, K. Kolibaba, D. Mahadevan, 2016, British journal of haematology.

Community-based phase II trial of pentostatin, cyclophosphamide, and rituximab (PCR) biochemotherapy in chronic lymphocytic leukemia and small lymphocytic lymphoma.

R. Dillman, M. Schreeder, J. Hon, 2007, Cancer biotherapy & radiopharmaceuticals.

Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

T. Miller, T. Kipps, J. Gabrilove, 2013 .

THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES RAPID TUMOR RESPONSES IN a PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL MALIGNANCIES

J. Leeds, P. Hamlin, J. Curnutte, 2017 .

UBLITUXIMAB AND IBRUTINIB FOR PREVIOUSLY TREATED GENETICALLY HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF THE GENUINE PHASE 3 STUDY

S. Kambhampati, J. Burke, I. Flinn, 2017 .

Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study.

J. Burke, K. Kolibaba, I. Flinn, 2017 .

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma.

J. Leonard, I. Flinn, S. de Vos, 2016, Blood advances.

A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K-Delta Inhibitor in Combination with Obinutuzumab Plus Chlorambucil, in Patients with Chronic Lymphocytic Leukemia

D. Mahadevan, M. Schreeder, P. Sportelli, 2015 .

A Phase 1 Study Of The Selective PI3Kδ Inhibitor Idelalisib (GS-1101) In Combination With Therapeutic Anti-CD20 Antibodies (Rituximab or Ofatumumab) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia

J. Leonard, I. Flinn, K. Rai, 2013 .

Long-Term Follow-up of a Phase 1 Study of Idelalisib (ZYDELIG®) in Combination with Anti-CD20 Antibodies (Rituximab [R] or Ofatumumab [O]) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

J. Leonard, I. Flinn, K. Rai, 2014 .

Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL).

Juswinder Singh, T. Kipps, J. Gabrilove, 2012 .

Long-term follow-up of a phase Ib trial of idelalisib (IDELA) in combination with chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory (R/R) CLL including pts with del17p/TP53 mutation.

J. Leonard, I. Flinn, K. Rai, 2015 .

Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

J. Nemunaitis, D. Mahalingam, L. Carter, 2019, Clinical Cancer Research.

A phase 1/2 trial of ublituximab, a novel anti‐CD20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab

J. Kolesar, D. Mahadevan, C. Deng, 2017, British journal of haematology.

A phase I dose-escalation trial of ublituximab (TG-1101), a novel anti-CD20 monoclonal antibody (mAb), for rituximab relapsed/refractory B-cell lymphoma patients.

C. Deng, O. O’Connor, J. Amengual, 2013 .

Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma

J. Hainsworth, D. Spigel, F. Greco, 2008, Cancer.

Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study

J. Leonard, I. Flinn, T. Jahn, 2012 .

Chemo-Immunotherapy Combination Of Idelalisib With Bendamustine/Rituximab Or Chlorambucil/Rituximab In Patients With Relapsed/Refractory CLL Demonstrates Efficacy and Tolerability

J. Leonard, I. Flinn, K. Rai, 2013 .

Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL.

J. Leonard, I. Flinn, K. Rai, 2013 .

A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies.

I. Flinn, S. de Vos, L. Miller, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced‐stage nonsmall cell lung cancer

S. Ramalingam, C. Belani, R. Steis, 2008, Cancer.

Successful treatment of thrombotic thrombocytopenia purpura by vincristine

M. Schreeder, J. Prchal, 1983, American journal of hematology.

Multiple buoyant densities of hepatitis A virus in cesium chloride gradients

D. Bradley, K. McCaustland, J. Maynard, 1977, Journal of medical virology.

Randomized controlled trial of irinotecan drug‐eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver‐limited metastasis

T. Crocenzi, C. Scoggins, S. Strasberg, 2015, Cancer.

Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by maintenance bevacizumab (B) in the treatment (tx) of limited-stage small cell lung cancer (LS-SCLC): Update of a phase II trial of the Minnie Pearl Cancer Research Network.

J. Hainsworth, D. Spigel, F. Greco, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Irinotecan Drug-Eluting Beads in the Treatment of Chemo-Naive Unresectable Colorectal Liver Metastasis with Concomitant Systemic Fluorouracil and Oxaliplatin: Results of Pharmacokinetics and Phase I Trial

C. Scoggins, D. Tomalty, C. Tatum, 2012, Journal of Gastrointestinal Surgery.

Dialysis encephalopathy and aluminum exposure: an epidemiologic analysis.

J. R. Hughes, P. Bennett, M. Favero, 1983, Journal of chronic diseases.

Phase 1 Clinical Safety, Pharmacokinetics (PK), and Activity of Apilimod Dimesylate (LAM-002A), a First-in-Class Inhibitor of Phosphatidylinositol-3-Phosphate 5-Kinase (PIKfyve), in Patients with Relapsed or Refractory B-Cell Malignancies

S. Ansell, L. Miller, H. Lichenstein, 2017 .

Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.

M. Berger, P. Zatloukal, C. Langer, 2014, Lung cancer.

EEG in dialysis encephalopathy

J. R. Hughes, M. Schreeder, 1980, Neurology.

Irinotecan, carboplatin, and imatinib in extensive stage small cell lung cancer: A phase II trial of the Minnie Pearl Cancer Research Network.

J. Hainsworth, H. Burris, D. Yardley, 2004, Journal of Clinical Oncology.

A prospective study of hepatitis B virus serologic markers and liver enzymes.

B. McMahon, T. Bender, W. Heyward, 1980, The Journal of infectious diseases.

Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced/metastatic non-small cell lung cancer (NSCLC)

S. Ramalingam, C. Belani, R. Steis, 2007 .

Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results

J. Vose, C. Flowers, S. O'brien, 2015 .

Phase I report from a multicenter trial of perifosine (PERI) + sunitinib (SUT) in patients with advanced cancers including renal cell carcinoma (RCC)

I. Henderson, S. Chawla, R. Birch, 2008 .

A phase I trial of ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody (mAb) in B-cell non-Hodgkin lymphoma patients with prior exposure to rituximab.

D. Mahadevan, C. Deng, O. O’Connor, 2014 .

A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC).

A. Szczesna, P. Zatloukal, A. Każarnowicz, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimizing obatoclax administration schedule: Safety and efficacy of 3-hour versus 24-hour infusion in combination with carboplatin and etoposide for patients with extensive-stage small cell lung cancer (ES-SCLC).

R. Salgia, J. Stephenson, A. Chiappori, 2010 .

A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC).

R. Salgia, J. Stephenson, A. Chiappori, 2009, Journal of Clinical Oncology.

5.43 Patterns of Nodal Response and Lymphocytosis in Patients with Previously Treated CLL Receiving the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101) Alone or in Combination with Rituximab (R) or Bendamustine (B)

J. Byrd, J. Leonard, I. Flinn, 2011 .

Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation

A. Zelenetz, J. Leonard, I. Flinn, 2013 .

Preliminary results of PI3Kδ inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine/rituximab in patients with previously treated mantle cell lymphoma (MCL).

J. Leonard, I. Flinn, S. Coutre, 2013 .

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma.

J. Leonard, I. Flinn, S. de Vos, 2016, Blood advances.

P2.06-017 Amethyst NSCLC Trial: Phase 2 Study of MGCD265 in Patients with Advanced or Metastatic NSCLC with Activating Genetic Alterations in MET: Topic: Phase II + NK

P. Jänne, D. Potvin, L. Cavanna, 2017 .

Weekly bortezomib in the treatment of patients (pts) with previously treated multiple myeloma: A phase II trial of the Minnie Pearl Cancer Research Network.

J. Hainsworth, R. Hermann, D. Spigel, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.